Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02992977 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability Study of AutoSynVax™ Vaccine in Subjects With Advanced Cancer
A Phase 1 study, sponsored by Agenus.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT02992977 is a Phase 1 study that was terminated before completion, run by Agenus. The registered enrollment target is 3 participants.
The verdict
NCT02992977, a Phase 1 study, was terminated before completion, sponsored by Agenus.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
Open-label Phase 1 study of AutoSynVax™ vaccine with QS-21 Stimulon® adjuvant in subjects with advanced cancer
Interventions
- BIOLOGICAL AutoSynVax™ vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2017-01 |
| Est. Completion | 2019-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02992977
The ClinicalTrials.gov registry entry for NCT02992977 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Agenus, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AutoSynVax™ vaccine is the first listed.
NCT02992977 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02992977 about?
NCT02992977 is a clinical study titled "Safety and Tolerability Study of AutoSynVax™ Vaccine in Subjects With Advanced Cancer". Open-label Phase 1 study of AutoSynVax™ vaccine with QS-21 Stimulon® adjuvant in subjects with advanced cancer
What is the current status of trial NCT02992977?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2017-01. Estimated completion is 2019-12.
What interventions are being tested in trial NCT02992977?
The interventions under investigation include: AutoSynVax™ vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT02992977?
This trial is sponsored by Agenus, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.